4D Molecular Therapeutics
FDMT
143 hedge funds and large institutions have $1.2B invested in 4D Molecular Therapeutics in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 32 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 37
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
2.3% less ownership
Funds ownership: 113.2% → 110.9% (-2.3%)
3% less funds holding
Funds holding: 147 → 143 (-4)
33% less capital invested
Capital invested by funds: $1.79B → $1.2B (-$590M)
74% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $4.54M
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$27M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$25.8M |
| 3 |
BlackRock
New York
|
+$15.4M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$6.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$17.1M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
-$15.5M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$8.57M |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$7.96M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.7M |
FDMT Hedge Fund Activity: Q2 2024 in Review
143 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2024, worth a combined $1.2B — down 33% from $1.79B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of FDMT and 29 opened new positions — a net loss of 3 holders — while 37 trimmed existing stakes and 54 added.
The largest buyer was Goldman Sachs, adding an estimated $27M. The largest seller was Braidwell, cutting an estimated $17.1M.
- 143 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2024, down from 147 in Q1 2024.
- Funds reported $1.2B of 4D Molecular Therapeutics stock for Q2 2024, down 33% quarter-over-quarter.
- 29 funds opened new 4D Molecular Therapeutics positions in Q2 2024 and 32 closed out, a net change of -3 holders.
- The largest 4D Molecular Therapeutics buyer in Q2 2024 was Goldman Sachs, an estimated $27M added.
- The largest 4D Molecular Therapeutics seller in Q2 2024 was Braidwell, an estimated $17.1M sold.
Based on aggregated 13F filings for Q2 2024.